Christina Magnussen
Overview
Explore the profile of Christina Magnussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Christalle E, Zeh S, Fuhres H, Schellhorn A, Hahlweg P, Zill J, et al.
BMJ Qual Saf
. 2024 Oct;
PMID: 39414377
Background: Patient-reported experience measures (PREMs) are valuable tools to evaluate patient-centredness (PC) from the patients' perspective. Despite their utility, a comprehensive PREM addressing PC has been lacking. To bridge this...
2.
Beer B, Keshtkaran S, Kellner C, Besch L, Sundermeyer J, Dettling A, et al.
ESC Heart Fail
. 2024 Aug;
11(6):3598-3606.
PMID: 39161275
Aim: Congestion is a major determinant of outcomes in acute heart failure. Its assessment is complex, making sufficient decongestive therapy a challenge. Residual congestion is frequent at discharge, increasing the...
3.
Unger E, Makarova N, Borof K, Schlieker P, Reinbold C, Aarabi G, et al.
Atherosclerosis
. 2024 Aug;
396:118526.
PMID: 39133970
Background And Aims: Adverse pregnancy outcomes (APO) have been related to increased cardiovascular (CV) risk and mortality in later life. Underlying pathomechanisms for the development of CV disease in these...
4.
Neumann J, Twerenbold R, Weimann J, Ballantyne C, Benjamin E, Costanzo S, et al.
JAMA
. 2024 May;
331(22):1898-1909.
PMID: 38739396
Importance: Identification of individuals at high risk for atherosclerotic cardiovascular disease within the population is important to inform primary prevention strategies. Objective: To evaluate the prognostic value of routinely available...
5.
Rillig A, Eckardt L, Borof K, Camm A, Crijns H, Goette A, et al.
Europace
. 2024 May;
26(6).
PMID: 38702961
Aims: Clinical concerns exist about the potential proarrhythmic effects of the sodium channel blockers (SCBs) flecainide and propafenone in patients with cardiovascular disease. Sodium channel blockers were used to deliver...
6.
Beer B, Kellner C, Sundermeyer J, Besch L, Dettling A, Kirchhof P, et al.
ESC Heart Fail
. 2024 Apr;
11(4):2249-2258.
PMID: 38632837
Aims: Acute heart failure (AHF) can result in worsening of heart failure (WHF), cardiogenic shock (CS), or death. Risk factors for these adverse outcomes are not well characterized. This study...
7.
Fabritz L, Chua W, Cardoso V, Al-Taie C, Borof K, Suling A, et al.
Cardiovasc Res
. 2024 Apr;
120(8):855-868.
PMID: 38613511
Aims: Atrial fibrillation (AF) and concomitant cardiometabolic disease processes interact and combine to lead to adverse events, such as stroke, heart failure, myocardial infarction, and cardiovascular death. Circulating biomolecules provide...
8.
Andrees V, Bei der Kellen R, Augustin M, Gallinat J, Harth V, Hoven H, et al.
PLoS One
. 2024 Apr;
19(4):e0301475.
PMID: 38593150
Background: Non-communicable diseases (NCDs) are responsible for many deaths. They are associated with several modifiable and metabolic risk factors and are therefore prone to significant regional variations on different scales....
9.
Lusebrink E, Gade N, Seifert P, Ceelen F, Veit T, Fohrer F, et al.
Clin Res Cardiol
. 2024 Apr;
113(12):1717-1732.
PMID: 38587564
Background And Aims: Candidate selection for lung transplantation (LuTx) is pivotal to ensure individual patient benefit as well as optimal donor organ allocation. The impact of coronary artery disease (CAD)...
10.
Billing A, Kim Y, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, et al.
Circulation
. 2023 Dec;
149(11):860-884.
PMID: 38152989
Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. Methods: To gain insights on primary effects of SGLT2i that...